H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24.Read More
ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported updated clinical data for brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had experienced disease progression on crizotinib therapy.
The data show that, of patients on the 180 mg regimen (Arm B) with a median follow-up of 8.3 months, 54% achieved a confirmed objective response, the trial’s primary endpoint. In this arm, the median progression free survival exceeded one year (12.9 months) in this post-crizotinib setting.Read More
ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals.
Under the accord, ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments, which will be allocated among the holders of Ciclofilin common stock.Read More
Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.
The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.Read More
Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday.
Exelixis is developing small molecule therapies for the treatment of cancer and is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases.Read More